von Willebrand factor-Coagulation factor VIII complex (VWF-FVIII complex) (VWF-FVIII complex)

The von Willebrand factor-Coagulation factor VIII complex is a vital circulating assembly essential for normal blood clotting and hemostasis. In this complex, von Willebrand factor (VWF) acts as a carrier protein that non-covalently binds to Coagulation factor VIII (FVIII), shielding it from premature degradation by activated protein C and preventing its rapid clearance (Lenting et al., 1998). This interaction is the primary determinant of FVIII's half-life in the blood, extending it from approximately 2 hours to 8-12 hours (StatPearls, 2023). When a blood vessel is injured, VWF facilitates the adhesion of platelets to the subendothelial matrix, while FVIII is released to serve as a cofactor in the intrinsic pathway of the coagulation cascade (UniProt, P04275). Deficiencies in these proteins lead to Hemophilia A or von Willebrand disease, characterized by impaired clot formation and excessive bleeding (NIH, 2024). Modern pharmacological interventions include replacement therapies using plasma-derived or recombinant versions of the complex, as well as bioengineered molecules like efanesoctocog alfa designed to optimize the stability and duration of FVIII activity (Lissitchkov et al., 2023).

Other names

VWF-FVIIIFactor VIII/von Willebrand factor complexFVIII-VWF complexAntihemophilic factor-von Willebrand factor complexFactor VIII:VWF

The primary mechanism involves the replacement of deficient proteins to restore hemostatic function. VWF stabilizes FVIII, protecting it from proteolytic cleavage and extending its half-life in plasma (Lenting et al., 1998). Novel therapies like efanesoctocog alfa utilize VWF fragments to decouple FVIII from endogenous VWF, bypassing the VWF-imposed half-life ceiling (Lissitchkov et al., 2023).